跳至主要内容

Medicilon 20th Anniversary - Keep pace with the times in innovation, thanks for having you

 Medicilon 20th.webp

In 2024, Medicilon will celebrate its 20th anniversary.  At the time of departure, Medicilon shouldered the dream of China's new drug research and development, took root in Zhangjiang, Shanghai, and embarked on a long journey to pursue the dream.  During the past 20 years, Medicilon has transformed into a leading one-stop biopharmaceutical preclinical R&D service CRO in China, and is moving forward with its goal of being a world-class CRO.

From chemical drugs to bi/multi-specific antibodies, ADCs, nucleic acids, mRNA, PROTAC, CGT and other fields, Medicilon continue to move towards the forefront of technology.  From the initial provision of chemical services to one-stop biopharmaceutical preclinical R&D services, Medicilon continue to expand the services.  From 0 to 420 IND approvals, Medicilon helps customers complete new drug clinical trial applications from China NMPA, US FDA, EU EMEA and Australia TGA.  These include the world's first inhaled nanobody drug for the treatment of moderate to severe asthma, the world's first innovative drug targeting RNA helicase, the world's first dual-antibody ADC drug that completely knocks out fucose, the world's first CAR-raNK cell therapy, China's first ADC targeting folate receptor FRα, China's first potassium ion competitive acid blocker Keprasen tablets, China's first clinically approved STING agonist, China's first original highly selective EP4 receptor antagonist, China's first Muc1-ADC drug and more.

Medicilon collaborates with pharmaceutical companies to enable one-stop preclinical research and development of new drugs, collaborates with universities to promote in-depth integration of industry, academia and research, and collaborates with AI pharmaceutical companies to accelerate drug discovery and development.  The Medicilon Academician Innovative Drug Maturation Center has established a new drug investment and financing support platform to provide financial support for new drug research and development.  Furthermore, Medicilon has established a new drug research and development trading platform to facilitate the transformation and trading of new drug research and development stage results, thereby building a new drug empowerment ecosystem and promoting the integration and orderly development of industry, academia, research and finance.  This is the joining and companionship of fellows that gathers the strength to be at the forefront and the efforts and perseverance of fellows that drive China's biopharmaceutical to the world.

Medicilon is grateful for the era, grateful for exploration, and grateful for having you along the way.

标签：

评论

发表评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...
发表评论
阅读全文

What is Toxicokinetics?

Toxicokinetics  is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms  toxicokinetics ,  pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...
发表评论
阅读全文